Latest News about Biotech
Recent news which mentions Biotech
Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why
October 31, 2023
From Benzinga
Pfizer Q3 Earnings: Drugmaker Swings To Quarterly Loss On COVID-19 Write-Offs, Sales Fall 42%
October 31, 2023
Tickers
PFE
From Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
From Benzinga
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
October 30, 2023
Tickers
RVPH
From Benzinga
Positive Momentum For VYNE Therapeutics' Psoriasis, Rheumatoid Arthritis Candidate - Analyst Expresses Encouragement
October 30, 2023
Tickers
VYNE
From Benzinga
Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today?
October 30, 2023
From Benzinga
Hope for Endometrial Cancer - GSK Drug Proves Effective in Increasing Survival Rates
October 30, 2023
Tickers
GSK
From Benzinga
GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales
October 30, 2023
From Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
October 30, 2023
Tickers
RVPH
From Benzinga
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
October 30, 2023
Tickers
DCPH
From Benzinga
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
October 30, 2023
Tickers
NVS
From Benzinga
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
October 30, 2023
From Benzinga
Cardio Diagnostics Leverages AI To Combat Cardiovascular Disease
October 30, 2023
Tickers
CDIO
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.